Table 7.
The effect of chemotherapy protocol on disease‐free interval (DFI) and survival times (STs) for the modified intent‐to‐treat analysis.
| Protocols | DFI | ST | ||||||
|---|---|---|---|---|---|---|---|---|
| Median DFI (days) | Crude HR | Adjusteda HR (95% CI) | P value | MST (days) | Crude HR | Adjustedb HR (95% CI) | P value | |
| CARBO4 | 282 | 1.02 | 1.13 (0.79, 1.60) | .50 | 299 | 0.88 | 0.83 (0.61, 1.13) | .23 |
| CARBO6 | 399 | 0.74 | 0.83 (0.57, 1.20) | .32 | 306 | 0.72c | 0.75 (0.54, 1.03) | .08 |
| CARBODOX6 | 302 | 0.93 | 0.99 (0.70, 1.40) | .97 | 314 | 0.80 | 0.85 (0.63, 1.13) | .26 |
| DOX5.2 | 269 | 1.0 | 1.0 (ref) | – | 252 | 1.0 | 1.0 (ref) | – |
| DOX5.3 | 302 | 0.90 | 1.08 (0.73, 1.62) | .69 | 241 | 0.91 | 1.00 (0.72, 1.39) | .99 |
| Carboplatin | 298 | 0.91 | 0.95 (0.73, 1.25) | .72 | 301 | 0.84 | 0.89 (0.71, 1.12) | .31 |
| Doxorubicin | 276 | 1.0 | 1.0 (ref) | – | 248 | 1.0 | 1.0 (ref) | – |
a
Adjusted for age at diagnosis, body weight, purebred dog, proximal humeral tumor location, and ALP.
b
Adjusted for age at diagnosis, body weight, purebred dog, proximal humeral tumor location, ALP, and treatment after development of metastatic disease.
c
Significant decrease in hazard ratio (HR) in the univariable analysis. Carboplatin, single agent carboplatin protocols (CARBO4 CARBO6); doxorubicin, single agent doxorubicin protocols (DOX5.2, DOX5.3).